Multi-Dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part I - Screening of Preservative Combinations.


Journal

Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R

Informations de publication

Date de publication:
02 2023
Historique:
received: 27 06 2022
revised: 03 09 2022
accepted: 03 09 2022
pubmed: 13 9 2022
medline: 18 1 2023
entrez: 12 9 2022
Statut: ppublish

Résumé

The development of multi-dose, subunit vaccine formulations can be challenging since antimicrobial preservatives (APs) often destabilize protein antigens. In this work, we evaluated Human Papillomavirus (HPV) Virus-Like Particles (VLPs) to determine if combining different APs used in approved parenteral products, each at lower concentrations than used alone, would maintain both antimicrobial effectiveness and antigen stability. To identify promising AP combinations, two different screening strategies were utilized: (1) empirical one-factor-at-a-time (OFAT) and (2) statistical design-of-experiments (DOE). Seven different APs were employed to screen for two- and three-AP combinations using high-throughput methods for antimicrobial effectiveness (i.e., microbial growth inhibition assay and a modified European Pharmacopeia method) and antigen stability (i.e., serotype-specific mAb binding to conformational epitopes of HPV6, 11, 16 VLPs by ELISA). The OFAT and DOE approaches were complementary, such that initial OFAT results (and associated lessons learned) were subsequently employed to optimize the combinations using DOE. Additional validation experiments confirmed the final selection of top AP-combinations predicted by DOE modeling. Overall, 20 candidate multi-dose formulations containing two- or three-AP combinations were down-selected. As described in Part 2 (companion paper), long-term storage stability profiles of aluminum-adjuvanted, quadrivalent HPV VLP formulations containing these lead candidate AP combinations are compared to single APs.

Identifiants

pubmed: 36096284
pii: S0022-3549(22)00396-3
doi: 10.1016/j.xphs.2022.09.001
pii:
doi:

Substances chimiques

Vaccines, Virus-Like Particle 0
Papillomavirus Vaccines 0
Adjuvants, Immunologic 0
Preservatives, Pharmaceutical 0
Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

446-457

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Kaushal Jerajani (K)

Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, 2030 Becker Drive, Lawrence, Kansas 66047, USA.

Ying Wan (Y)

Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, 2030 Becker Drive, Lawrence, Kansas 66047, USA.

Ozan S Kumru (OS)

Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, 2030 Becker Drive, Lawrence, Kansas 66047, USA.

Swathi R Pullagurla (SR)

Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, 2030 Becker Drive, Lawrence, Kansas 66047, USA.

Prashant Kumar (P)

Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, 2030 Becker Drive, Lawrence, Kansas 66047, USA.

Nitya Sharma (N)

Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, 2030 Becker Drive, Lawrence, Kansas 66047, USA.

Oluwadara Ogun (O)

Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, 2030 Becker Drive, Lawrence, Kansas 66047, USA.

Shweta Mapari (S)

Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, 2030 Becker Drive, Lawrence, Kansas 66047, USA.

Sarah Brendle (S)

Department of Pathology, Pennsylvania State University College of Medicine, 500 University Drive, Hershey, Pennsylvania 17033, USA.

Neil D Christensen (ND)

Department of Pathology, Pennsylvania State University College of Medicine, 500 University Drive, Hershey, Pennsylvania 17033, USA.

Saurabh Batwal (S)

Serum Institute of India Pvt. Ltd., Pune, India.

Mustafa Mahedvi (M)

Serum Institute of India Pvt. Ltd., Pune, India.

Harish Rao (H)

Serum Institute of India Pvt. Ltd., Pune, India.

Vikas Dogar (V)

Serum Institute of India Pvt. Ltd., Pune, India.

Rahul Chandrasekharan (R)

Serum Institute of India Pvt. Ltd., Pune, India.

Umesh Shaligram (U)

Serum Institute of India Pvt. Ltd., Pune, India.

Sangeeta B Joshi (SB)

Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, 2030 Becker Drive, Lawrence, Kansas 66047, USA.

David B Volkin (DB)

Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, 2030 Becker Drive, Lawrence, Kansas 66047, USA. Electronic address: volkin@ku.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH